Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given a consensus rating of “Moderate Buy” by the sixteen research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.7692.

Several brokerages have recently weighed in on CMPX. Piper Sandler raised their target price on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research note on Monday, June 1st. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th.

Compass Therapeutics Trading Down 5.6%

NASDAQ CMPX opened at $1.85 on Wednesday. The company’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $3.10. Compass Therapeutics has a 52 week low of $1.61 and a 52 week high of $6.88. The stock has a market cap of $333.17 million, a P/E ratio of -4.62 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts expect that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently added to or reduced their stakes in CMPX. BlackRock Inc. bought a new stake in Compass Therapeutics during the second quarter valued at $24,707,000. BVF Inc. IL lifted its position in shares of Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after buying an additional 3,014,842 shares during the last quarter. Palo Alto Investors LP acquired a new position in shares of Compass Therapeutics in the 2nd quarter valued at about $12,771,670. Blue Owl Capital Holdings LP boosted its holdings in shares of Compass Therapeutics by 33.8% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,466,525 shares of the company’s stock valued at $18,615,000 after buying an additional 875,000 shares during the period. Finally, Sofinnova Investments Inc. grew its position in shares of Compass Therapeutics by 65.9% during the 4th quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock valued at $18,072,000 after buying an additional 1,336,560 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.